Takayasu Arteritis Activity Evaluation by Ultrafast Ultrasound Imaging

Learn more about:
Related Clinical Trial
Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis Comparison of Tofacitinib and Methotrexate in Takayasu’s Arteritis A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK) Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis A Pilot Study in Severe Patients With Takayasu Arteritis. Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients Drug-coated Balloon for Takayasu Arteritis Associated Renal Artery Stenosis The Registry Study of Takayasu Arteritis in East China Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases A Registry Study on Biomarkers of Takayasu’s Arteritis (ARSBTA) Infliximab Biosimilar in Takayasu’s Arteritis Exercise in Juvenile Takayasu Disease Pulmonary Artery Involvement in Takayasu’s Arteritis Anti-inflammatory Treatment for Inactive Takayasu Arteritis Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis Aerobic Capacity and Strength Exercise in Takayasu’s Arteritis Use of MRI and PET for Assessing Disease Activity in Takayasu’s Arteritis Impact and Utility of PET Versus Clinical Score for the Assessment of Inflammatory Activity in Takayasu Arteritis Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu’s Arteritis Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis Registration Study of Takayasu’s Arteritis in China Determining Disease Activity Biomarkers in Individuals With Takayasu’s Arteritis Takayasu Arteritis Activity Evaluation by Ultrafast Ultrasound Imaging China Takayasu Arteritis Registry (CTA Registry) Takayasu Arteritis Clinical Trial in China

Brief Title

Takayasu Arteritis Activity Evaluation by Ultrafast Ultrasound Imaging

Official Title

Takayasu Arteritis Activity Evaluation by Ultrafast Ultrasound Imaging

Brief Summary

      The general activity of Takayasu vasculitis is correlated with the perfusion rate of the
      carotid arterial wall. This can be quantified with ultrafast ultrasound imaging in sensitive
      Doppler sequence associated with the concomitant injection of microbubbles (SonoVue®).

      The hypothesis is that the carotid artery wall flow parameters obtained with ultrafast
      ultrasound imaging make possible to discriminate an active disease from an inactive disease
      because of the fibrous sequential arterial thickening. Thus, to improve the evaluation of
      Takayasu vasculitis activity and to refine the criteria for response to the various
      immunomodulatory treatments used.

Detailed Description

      Takayasu vasculitis is a systemic inflammatory disease that causes progressive thickening and
      stenosis of large and medium-sized arteries (the aorta and its branches, as well as the
      pulmonary arteries). The classic histological aspect corresponds to a chronic inflammation
      localized to the arterial wall. Vascular imaging plays an important role in the diagnosis and
      monitoring of these patients. Although Doppler ultrasound, MRI and computed tomography can
      simply assess recognized inflammation criteria, such as thickening or signal intensity of the
      arterial wall, to recognize Takayasu vasculitis in the early stages of inflammation of the
      disease, there is no clear correlation between the presence of these signs and the activity
      or progression of the disease.

      However, assessment of Takayasu vasculitis activity is difficult in daily practice because
      symptoms, physical examination, and biological parameters may not reliably reflect vascular
      inflammation. Finally, unlike other small- and medium-vessel vasculitis, histology is rarely
      available to diagnose and evaluate the activity of patients with Takayasu vasculitis.

      In order to identify local markers of disease activity, contrast ultrasound (with injection
      of SonoVue® microbubbles) has shown its ability to visualize the presence of micro-vessels
      within the carotid wall. Ultrafast Ultrasound Imaging provides a more accurate exploration of
      the small vasorum vessels compared to contrast ultrasound. This technology has already been
      the subject of a study on cerebral microvasculature. In its application on the carotid wall,
      it will allow easier quantification than conventional ultrasound, by a signal analysis in
      ultrafast Doppler and not on the gray level, much more variable.

Study Type


Primary Outcome

Quantification of the vascularity

Secondary Outcome

 Evaluate average local elasticity of the ultrafast imaging results regarding the disease activity


Takayasu Arteritis


UltraFast ultrasound

Study Arms / Comparison Groups

 Active Takayasu disease
Description:  UltraFast ultrasound will be performed in the usual health care, with the evaluation of carotid artery disease by Doppler ultrasound in patients hospitalized for Takayasu Arteritis Assessment.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Diagnostic Test

Estimated Enrollment


Start Date

January 8, 2020

Completion Date

December 31, 2021

Primary Completion Date

December 31, 2021

Eligibility Criteria

        Inclusion Criteria:

          -  Takayasu disease diagnosed according to the American College of Rheumatology 1990

        Exclusion Criteria:

          -  Carotid damaged not related to Takayasu disease: atherosclerosis, post-radiation

          -  Contraindication with the use of SonoVue®:

               -  Unstable ischemic heart disease (recent myocardial infarction, resting angina
                  within 7 days)

               -  Acute heart failure

               -  Stage III or IV heart failure

               -  Severe rhythm disorders

               -  Patients with right-left shunt

               -  Severe pulmonary arterial hypertension (pulmonary arterial pressure> 90 mmHg)

               -  Uncontrolled systemic hypertension

               -  Patients with respiratory distress syndrome

               -  Severe chronic obstructive pulmonary disease.

               -  Acute endocarditis

               -  Heart valve prostheses

               -  Sepsis

               -  Hypercoagulation and / or recent thromboembolic events

               -  Terminal stage of kidney or liver disease.

               -  Hypersensitivity to sulfur hexafluoride or any of the other ingredients of

          -  Pregnancy or breastfeeding.

          -  Participation in another biomedical research protocol.

          -  Refusal or incapacitation of language or psychic to sign informed consent




18 Years - N/A

Accepts Healthy Volunteers



Emmanuel MESSAS, MD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

French Cardiology Society


 Institut National de la Santé Et de la Recherche Médicale, France

Study Sponsor

Emmanuel MESSAS, MD, Principal Investigator, Hôpital Européen Georges-Pompidou

Verification Date

March 2022